Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRB | O95718 | 2/20 | 0.39 |
| ▸ | ESRRA | P11474 | 2/20 | 0.39 |
| ▸ | DHODH | Q02127 | 5/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | PRF1 | P14222 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | GALR1 | P47211 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3198274 | 0.89 | ESRRB (0.36) | ESRRBESRRAESR1CYP11B1CYP11B2 | |
| SCHEMBL3187354 | 0.87 | ESRRB (0.52) | ESRRBESRRAESR1CYP11B1CYP11B2 | |
| SCHEMBL3198596 | 0.85 | ESRRB (0.38) | ESRRBESRRAESR1PRF1 | |
| SCHEMBL3190686 | 0.83 | ESRRB (0.38) | ESRRBESRRAESR1CYP11B1CYP11B2 | |
| SCHEMBL3195539 | 0.82 | ESRRB (0.50) | ESRRBESRRACYP11B1CYP11B2PRF1 | |
| SCHEMBL3188483 | 0.81 | ALOX5 (0.39) | ESRRBESRRAESR1CYP11B1CYP11B2 | |
| SCHEMBL3186259 | 0.81 | ESRRB (0.38) | ESRRBESRRAESR1CYP11B1CYP11B2 | |
| SCHEMBL3191309 | 0.78 | ESR2 (0.41) | ESRRBESRRAESR1 | |
| SCHEMBL3185517 | 0.77 | ESR1 (0.40) | ESRRBESRRAESR1CYP11B1CYP11B2 | |
| SCHEMBL3186636 | 0.77 | CYP17A1 (0.38) | ESRRBESRRAESR1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157492-B2 | Dibenzo chromene derivatives and their use as ERβ selective ligands | WYETH (US) | 2007-01-02 | — | — | US | claimed |
| EP-1718630-A1 | DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ER&bgr; SELECTIVE LIGANDS | Wyeth a Corporation of the State of Delaware (US) | 2006-11-08 | — | — | EP | claimed |
| US-20050234074-A1 | Dibenzo chromene derivatives and their use as ERbeta selective ligands | WYETH (US) | 2005-10-20 | — | — | US | claimed |
| WO-2005082880-A1 | DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ERβ SELECTIVE LIGANDS | WYETH (US) | 2005-09-09 | — | — | WO | claimed |
| US-7671084-B2 | Dibenzo chromene derivatives and their use as ERβ selective ligands | WYETH (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070049605-A1 | Dibenzo chromene derivatives and their use as ERbeta selective ligands | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
| US-7157492-B2 | Dibenzo chromene derivatives and their use as ERβ selective ligands | WYETH (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050234074-A1 | Dibenzo chromene derivatives and their use as ERbeta selective ligands | WYETH (US) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234074-A1 | Dibenzo chromene derivatives and their use as ERbeta selective ligands | ESR2, ESR1, ESRRB | ESRRB 3/4885ESRRA 4/4885DHODH 2971/4885 |
| US-20070049605-A1 | Dibenzo chromene derivatives and their use as ERbeta selective ligands | ESR2, ESR1, ESRRA | ESRRB 4/4885ESRRA 3/4885DHODH 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.